keyword
MENU ▼
Read by QxMD icon Read
search

David P. Steensma

keyword
https://www.readbyqxmd.com/read/29757456/cancer-research-in-the-united-states-a-critical-review-of-current-status-and-proposal-for-alternative-models
#1
Hagop M Kantarjian, Ferran Prat, David P Steensma, Razelle Kurzrock, David J Stewart, Mikkael A Sekeres, Joseph Leveque
No abstract text is available yet for this article.
May 14, 2018: Cancer
https://www.readbyqxmd.com/read/29741506/recent-advances-in-the-cellular-and-molecular-understanding-of-myelodysplastic-syndromes-implications-for-new-therapeutic-approaches
#2
Andrew M Brunner, David P Steensma
It has been more than 10 years since any new disease-modifying therapies have received regulatory approval for indications related to myelodysplastic syndromes (MDS). Advances in our collective biological understanding of MDS in the last decade, however, have made it possible to hope that effective therapeutics can be designed to improve MDS-associated cytopenias and patients' quality of life, and perhaps even delay clonal progression and extend survival. Classes of MDS-associated mutations and disordered biological pathways targeted by developmental therapeutics include the following: aberrant messenger RNA splicing, neomorphic enzymes in the citric acid cycle with oncogenic activity, overactivated tyrosine and serine-threonine kinases, epigenetic and chromatin remodeling alterations, abnormal telomere dynamics, and failed protection of DNA integrity...
January 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29728209/j%C3%A3-ns-jacob-berzelius-a-father-of-chemistry
#3
Robert A Kyle, David P Steensma
No abstract text is available yet for this article.
May 2018: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/29724895/high-npm1-mutant-allele-burden-at-diagnosis-predicts-unfavorable-outcomes-in-de-novo-aml
#4
Sanjay S Patel, Frank C Kuo, Christopher J Gibson, David P Steensma, Robert J Soiffer, Edwin P Alyea, Yi-Bin A Chen, Amir T Fathi, Timothy A Graubert, Andrew M Brunner, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Valentina Nardi, Robert P Hasserjian, Olga K Weinberg
Acute myeloid leukemia (AML) with mutated NPM1 is a newly recognized separate entity in the revised 2016 WHO classification, and is associated with a favorable prognosis. While previous studies have evaluated NPM1 in a binary fashion, little is known about the significance of its mutant allele burden at diagnosis, nor has the effect of co-mutations (other than FLT3) been extensively evaluated. We retrospectively used targeted sequencing data from 109 de novo AML patients with mutated NPM1 to evaluate the potential significance of NPM1 variant allele frequency (VAF), co-mutations, and clinical parameters on patient outcomes...
May 3, 2018: Blood
https://www.readbyqxmd.com/read/29703819/new-insights-from-studies-of-clonal-hematopoiesis
#5
Christopher J Gibson, David P Steensma
Clonal hematopoiesis (CH) describes an asymptomatic expansion of blood cells descended from a single hematopoietic stem cell. Recent studies have shown that CH increases in frequency with aging, and is often driven by somatic mutations in genes that are recurrently mutated in hematologic malignancies. When CH is associated with a mutation in a leukemia-associated gene at a variant allele frequency of 0.02 or greater, it is termed "clonal hematopoiesis of indeterminate potential" (CHIP).  CHIP has a 0...
April 27, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29667455/beliefs-and-practice-patterns-in-hyperleukocytosis-management-in-acute-myeloid-leukemia-a-large-u-s-web-based-survey
#6
Maximilian Stahl, Alexander Pine, Jeanne E Hendrickson, Mark R Litzow, Selina M Luger, Richard M Stone, Harry P Erba, Tae Kon Kim, Mikkael A Sekeres, David P Steensma, Rami S Komrokji, Steven D Gore, Amer M Zeidan
No abstract text is available yet for this article.
April 18, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29643232/increased-neutrophil-extracellular-trap-formation-promotes-thrombosis-in-myeloproliferative-neoplasms
#7
Ofir Wolach, Rob S Sellar, Kimberly Martinod, Deya Cherpokova, Marie McConkey, Ryan J Chappell, Alexander J Silver, Dylan Adams, Cecilia A Castellano, Rebekka K Schneider, Robert F Padera, Daniel J DeAngelo, Martha Wadleigh, David P Steensma, Ilene Galinsky, Richard M Stone, Giulio Genovese, Steven A McCarroll, Bozenna Iliadou, Christina Hultman, Donna Neuberg, Ann Mullally, Denisa D Wagner, Benjamin L Ebert
Thrombosis is a major cause of morbidity and mortality in Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), clonal disorders of hematopoiesis characterized by activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling. Neutrophil extracellular trap (NET) formation, a component of innate immunity, has been linked to thrombosis. We demonstrate that neutrophils from patients with MPNs are primed for NET formation, an effect blunted by pharmacological inhibition of JAK signaling...
April 11, 2018: Science Translational Medicine
https://www.readbyqxmd.com/read/29590545/clonal-hematopoiesis-after-induction-chemotherapy-for-acute-myeloid-leukemia
#8
EDITORIAL
David P Steensma, Benjamin L Ebert
New England Journal of Medicine, Volume 378, Issue 13, Page 1244-1245, March 2018.
March 29, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29502575/christian-albert-theodor-billroth-founder-of-abdominal-surgery
#9
Robert A Kyle, David P Steensma
No abstract text is available yet for this article.
March 2018: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/29451319/prognosis-in-myelodysplastic-syndromes-the-attractions-and-limitations-of-simplicity
#10
David P Steensma
No abstract text is available yet for this article.
May 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29331635/sotatercept-with-long-term-extension-for-the-treatment-of-anaemia-in-patients-with-lower-risk-myelodysplastic-syndromes-a-phase-2-dose-ranging-trial
#11
Rami Komrokji, Guillermo Garcia-Manero, Lionel Ades, Thomas Prebet, David P Steensma, Joseph G Jurcic, Mikkael A Sekeres, Jesus Berdeja, Michael R Savona, Odile Beyne-Rauzy, Aspasia Stamatoullas, Amy E DeZern, Jacques Delaunay, Gautam Borthakur, Robert Rifkin, Thomas E Boyd, Abderrhamane Laadem, Bond Vo, Jennie Zhang, Marie Puccio-Pick, Kenneth M Attie, Pierre Fenaux, Alan F List
BACKGROUND: Myelodysplastic syndromes are characterised by ineffective erythropoiesis leading to anaemia. Sotatercept (ACE-011) is a novel activin receptor type IIA fusion protein that acts as a ligand trap to neutralise negative regulators of late-stage erythropoiesis. The aim of the study was to establish a safe and effective dose of sotatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes. METHODS: This open-label, multicentre, dose-ranging, phase 2 trial took place at 11 treatment centres in the USA and France...
February 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29311715/the-bone-marrow-niche-in-mds-and-mgus-implications-for-aml-and-mm
#12
REVIEW
Irene M Ghobrial, Alexandre Detappe, Kenneth C Anderson, David P Steensma
Several haematological malignancies, including multiple myeloma (MM) and acute myeloid leukaemia (AML), have well-defined precursor states that precede the development of overt cancer. MM is almost always preceded by monoclonal gammopathy of undetermined significance (MGUS), and at least a quarter of all patients with myelodysplastic syndromes (MDS) have disease that evolves into AML. In turn, MDS are frequently anteceded by clonal haematopoiesis of indeterminate potential (CHIP). The acquisition of additional genetic and epigenetic alterations over time clearly influences the increasingly unstable and aggressive behaviour of neoplastic haematopoietic clones; however, perturbations in the bone-marrow microenvironment are increasingly recognized to have key roles in initiating and supporting oncogenesis...
April 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/29304925/%C3%A3-lvaro-alvim-radiologist-and-brazilian-martyr-to-science
#13
Ahmadreza Afshar, David P Steensma, Robert A Kyle
No abstract text is available yet for this article.
January 2018: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/29296849/risk-and-timing-of-cardiovascular-death-among-patients-with-myelodysplastic-syndromes
#14
Andrew M Brunner, Traci M Blonquist, Gabriela S Hobbs, Philip C Amrein, Donna S Neuberg, David P Steensma, Gregory A Abel, Amir T Fathi
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders associated with progression to leukemia and poor survival. Clonal hematopoiesis in people without an MDS diagnosis carries an increased risk of cardiovascular death. Many clonally restricted mutations are shared between patients with MDS and those with non-MDS clonal hematopoiesis; therefore, we evaluated the risk of cardiovascular death among patients with MDS. We evaluated adults with MDS in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute and compared them with the general population living in the same states...
October 24, 2017: Blood Advances
https://www.readbyqxmd.com/read/29296824/systematic-stat3-sequencing-in-patients-with-unexplained-cytopenias-identifies-unsuspected-large-granular-lymphocytic-leukemia
#15
Elizabeth A Morgan, Mark N Lee, Daniel J DeAngelo, David P Steensma, Richard M Stone, Frank C Kuo, Jon C Aster, Christopher J Gibson, R Coleman Lindsley
No abstract text is available yet for this article.
September 26, 2017: Blood Advances
https://www.readbyqxmd.com/read/29236583/the-raven
#16
David P Steensma
No abstract text is available yet for this article.
December 13, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29156198/the-evolving-role-of-genomic-testing-in-assessing-prognosis-of-patients-with-myelodysplastic-syndromes
#17
REVIEW
David P Steensma
The introduction into routine hematology-oncology clinical practice of molecular genetic testing assays based on next-generation sequencing platforms is prompting reassessment of the importance of molecular assay results in comparison to existing disease-specific risk stratification tools based on clinical assessment and light microscopy. For patients with myelodysplastic syndromes (MDS), the most commonly used tools for prognostication currently include the International Prognostic Scoring System (IPSS) and the Revised IPSS (IPSS-R), which are based on marrow blast proportion, number and degree of cytopenias, and the metaphase karyotype...
December 2017: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/29119643/a-phase-i-study-of-lenalidomide-plus-chemotherapy-with-mitoxantrone-etoposide-and-cytarabine-for-the-reinduction-of-patients-with-acute-myeloid-leukemia
#18
Daniel J DeAngelo, Andrew M Brunner, Lillian Werner, David Avigan, Amir T Fathi, Adam S Sperling, Abigail Washington, Dina Stroopinsky, Jacalyn Rosenblatt, Malgorzata McMasters, Katarina Luptakova, Martha Wadleigh, David P Steensma, Gabriela S Hobbs, Eyal C Attar, Philip C Amrein, Benjamin L Ebert, Richard M Stone, Karen K Ballen
Patients with relapsed AML have a poor prognosis and limited responses to standard chemotherapy. Lenalidomide is an immunomodulatory drug that may modulate anti-tumor immunity. We performed a study to evaluate the safety and tolerability of lenalidomide with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory AML. Adult patients with relapsed/refractory AML were eligible for this phase I dose-escalation study. We enrolled 35 patients using a "3 + 3" design, with a 10 patient expansion cohort at the maximum tolerated dose (MTD)...
February 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29101943/thalassemia-and-thomas-benton-cooley
#19
Salahuddin Siddiqui, David P Steensma, Robert A Kyle
No abstract text is available yet for this article.
November 2017: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/28870369/charles-fletcher-the-centaur-company-and-proprietary-medicine-revenue-stamps
#20
David P Steensma, Robert A Kyle
No abstract text is available yet for this article.
September 2017: Mayo Clinic Proceedings
keyword
keyword
64671
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"